Lv21
120 积分 2025-04-14 加入
Adjuvant immune checkpoint blockade revisited
2小时前
已完结
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit
4小时前
已完结
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
2个月前
已关闭
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
2个月前
已完结
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
2个月前
已完结
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
2个月前
已完结
Cancer screening programs in Japan: Progress and challenges
3个月前
已完结
Evaluation of Pathological Response and Surgical Safety of Total Neoadjuvant Therapy for Patients with Clinical Stage III Gastric Cancer in a Real-world Setting
4个月前
已完结
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
4个月前
已关闭
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
7个月前
已完结
皖公网安备34019202002308
